Because existing drugs can activate RAF signalling in cancer cells through the RAF ‘paradox’ [12], other types of inhibitor are in development for more robust inhibition of RAF kinases (e.g. Type 2 inhibitors and BRAF-PROTAC degraders that target BRAF to the proteosome) [55]. The gene discussed is RAF1; the disease is cancer.